C12N 2710/16634
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2710/16634 (Use of virus or viral component as vaccine) appears on 291 US grants and 381 published applications in this corpus.
Search patents in C12N- Granted patents
- 291
- Published applications
- 381
- Assignees
- 220
- Inventors
- 658
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 2 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 3 | 0 |
| 1987 | 0 | 0 |
| 1988 | 3 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 4 | 0 |
| 1998 | 12 | 0 |
| 1999 | 9 | 0 |
| 2000 | 8 | 0 |
| 2001 | 5 | 2 |
| 2002 | 11 | 14 |
| 2003 | 8 | 11 |
| 2004 | 4 | 15 |
| 2005 | 8 | 7 |
| 2006 | 5 | 8 |
| 2007 | 3 | 6 |
| 2008 | 7 | 10 |
| 2009 | 5 | 13 |
| 2010 | 5 | 18 |
| 2011 | 8 | 15 |
| 2012 | 10 | 22 |
| 2013 | 10 | 18 |
| 2014 | 17 | 14 |
| 2015 | 10 | 20 |
| 2016 | 11 | 14 |
| 2017 | 19 | 18 |
| 2018 | 12 | 13 |
| 2019 | 21 | 15 |
| 2020 | 9 | 22 |
| 2021 | 10 | 20 |
| 2022 | 14 | 11 |
| 2023 | 8 | 24 |
| 2024 | 5 | 24 |
| 2025 | 8 | 13 |
| 2026 | 3 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof11 Aug 2026US 12,702,707 B2The Trustees of the University of Pennsylvania
- Treatment using oncolytic virus21 Jul 2026US 12,685,767 B2Replimune Limited
- Antigenic glycoprotein E polypeptides, compositions, and methods of use thereof17 Feb 2026US 12,551,552 B2Merck Sharp & Dohme Corp.
- Extracellular vesicles for vaccine delivery23 Dec 2025US 12,502,427 B2Lonza Sales AG
- Vaccines for recurrent respiratory papillomatosis and methods of using the same25 Nov 2025US 12,478,667 B2Inovio Pharmaceuticals, Inc.
- Compositions for delivery of liver stage antigens and related methods3 Sep 2026US 2026/0256898 A1BioNTech SE
- Hsv gene expression vector and bxb1 integrase-mediated recombination system for high-throughput cloning27 Aug 2026US 2026/0250643 A1Albert Einstein College of Medicine
- Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein c, glycoprotein d, and glycoprotein e antigens and related methods13 Aug 2026US 2026/0232791 A1BioNTech SE
- Triple mrna vaccine for preventing feline rhinotracheitis, feline caliciviral disease, and feline panleukopenia, and preparation method thereof6 Aug 2026US 2026/0224690 A1Zhejiang University
- Mrna vaccine for herpes simplex virus6 Aug 2026US 2026/0224693 A1University of Houston System
Most cited
By later US patents
- Method for immunizing animals with synthetically modified vaccinia virus240US 4,722,848 AHealth Research, Inc. · 1988
- Hybrid particle immunogens118US 4,722,840 AChiron Corporation · 1988
- Adjuvant systems and vaccines92US 7,357,936 B1SmithKline Beecham Biologicals s.a. · 2008
- Vaccine compositions containing liposomes86US 5,709,879 AChiron Corporation · 1998
- Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus80US 6,013,433 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 2000